Drug intelligence / Profile preview

R&D712 LAI 3M

Development stage: Preclinical
Lead developer: Bostal Pharma
Modality: Small Molecules
Administration: Intramuscular

Overview

R&D712 LAI 3M is a long-acting injectable (LAI) formulation of an antipsychotic medication being developed by Bostal Pharma for the treatment of schizophrenia. Utilizing the 505(b)(2) regulatory pathway, the drug is designed to provide sustained therapeutic levels of the active ingredient over a three-month period following a single administration. This formulation aims to improve patient adherence and clinical outcomes by reducing the frequency of dosing compared to standard oral or shorter-acting injectable antipsychotics. As of 2024, the candidate is in the early stages of development, with Phase 1 clinical trials projected to begin in 2027 and an NDA filing targeted for 2030.

Beyond the preview

Go deeper on R&D712 LAI 3M.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on R&D712 LAI 3M.

Explore the full profile